Prognostic markers for acute heart failure

Pascual Figal, Domingo A.; Caballero, Luis; Sanchez Mas, Jesus; Lax Pérez, Antonio Manuel

Publication:
Prognostic markers for acute heart failure

dc.contributor.author	Pascual Figal, Domingo A.
dc.contributor.author	Caballero, Luis
dc.contributor.author	Sanchez Mas, Jesus
dc.contributor.author	Lax Pérez, Antonio Manuel
dc.contributor.department	Medicina
dc.date.accessioned	2024-01-22T17:20:23Z
dc.date.available	2024-01-22T17:20:23Z
dc.date.copyright	© 2013 Informa UK, Ltd.
dc.date.issued	2013-06-25
dc.description.abstract	Introduction: Acute heart failure (AHF) is the leading cause of hospitalization in patients over 65 years, representing a heterogenic syndrome and a major burden, as it is associated with elevated health expenditures and high rates of mortality and readmission. Areas covered: This article provides a review of individual markers for risk stratification, including clinical, cardiorenal, hemodynamic, neurohormonal and cardiac biomarkers. In addition, aspects as complementary value, monitoring, risk models and events prediction are analyzed. Expert opinion: In clinical practice, risk stratification of AHF is complex and relies on the integration of bedside evaluation and laboratory biomarkers. Measures of congestion and perfusion, renal function, natriuretic peptides and cardiac troponins have become standard risk markers of death and/or readmission. However, there are numerous research findings that do not translate into an improved clinical management of individuals and a reduction of health costs. Research on this field needs to be redirected in a prospective manner in order to evaluate risk models in the emergency department. This would allow safe identification of patients at lower risk - who could be transferred and managed in out-patient facilities - as well as those biomarkers that, by reflecting pathophysiological routes, could be used as a guide to related therapeutics for improving outcomes. In addition, the identification of specific markers and models closely related with the risk of recurrent AHF is mandatory. Consequently, it is the time for clinicians working in networks to assume a leading role in translating risk assessment in AHF into clinical practice.	es
dc.format	application/pdf	es
dc.format.extent	14	es
dc.identifier.citation	Expert opinion on medical diagnostics
dc.identifier.doi	https://doi.org/10.1517/17530059.2013.814638
dc.identifier.issn	1753-0067
dc.identifier.issn	1753-0059
dc.identifier.uri	http://hdl.handle.net/10201/137549
dc.language	eng	es
dc.relation	Sin financiación externa a la Universidad	es
dc.rights.accessRights	info:eu-repo/semantics/restrictedAccess
dc.subject	Acute heart failure	es
dc.subject	Biomarkers	es
dc.subject	Prognosis	es
dc.subject	Risk	es
dc.title	Prognostic markers for acute heart failure	es
dc.type	info:eu-repo/semantics/article	es
dc.type.version	info:eu-repo/semantics/publishedVersion
dspace.entity.type	Publication	es